Fatty acid biosynthesis is involved in the production of hepatitis B virus particles
Autor: | Yuichi Akahori, Yasunori Nio, Makoto Hijikata, Hitomi Okamura, Koichi Watashi, Sulyi Kim, Takaji Wakita |
---|---|
Rok vydání: | 2016 |
Předmět: |
DNA Replication
0301 basic medicine Hepatitis B virus Hepatitis C virus Biophysics Virus Replication medicine.disease_cause Biochemistry Hepatitis B virus PRE beta law.invention Palmitic acid 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine law medicine Humans Cytotoxicity Molecular Biology chemistry.chemical_classification biology Fatty Acids Virion virus diseases Hep G2 Cells Cell Biology Hepatitis B Virology Molecular biology digestive system diseases Fatty acid synthase 030104 developmental biology Enzyme Liver chemistry 030220 oncology & carcinogenesis DNA Viral Host-Pathogen Interactions biology.protein Recombinant DNA |
Zdroj: | Biochemical and Biophysical Research Communications. 475:87-92 |
ISSN: | 0006-291X |
DOI: | 10.1016/j.bbrc.2016.05.043 |
Popis: | Hepatitis B virus (HBV) proliferates in hepatocytes after infection, but the host factors that contribute to the HBV lifecycle are poorly understood at the molecular level. We investigated whether fatty acid biosynthesis (FABS), which was recently reported to contribute to the genomic replication of hepatitis C virus, plays a role in HBV proliferation. We examined the effects of inhibitors of the enzymes in the FABS pathway on the HBV lifecycle by using recombinant HBV-producing cultured cells and found that the extracellular HBV DNA level, reflecting HBV particle production, was decreased by treatment with inhibitors suppressed the synthesis of long-chain saturated fatty acids with little cytotoxicity. The reduced HBV DNA level was reversed when palmitic acid, which is the product of fatty acid synthase (FAS) during FABS, was used simultaneously with the inhibitor. We also observed that the amount of intracellular HBV DNA in the cells was increased by FAS inhibitor treatment, suggesting that FABS is associated with HBV particle production but not its genome replication. This suggests that FABS might be a potent target for anti-HBV drug with a mode of action different from current HBV therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |